Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) Shares Outstanding (Diluted Average) (2016 - 2025)

Immucell's Shares Outstanding (Diluted Average) history spans 16 years, with the latest figure at $9.0 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 10.52% year-over-year to $9.0 million; the TTM value through Dec 2025 reached $9.0 million, up 10.52%, while the annual FY2025 figure was $9.0 million, 10.52% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $9.0 million in Q4 2025 per ICCC's latest filing, roughly flat from $9.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $9.0 million in Q3 2025 to a low of $7.2 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $7.9 million, with a median of $7.7 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): fell 0.97% in 2022, then rose 14.38% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $7.6 million in 2021, then increased by 2.01% to $7.7 million in 2022, then increased by 0.03% to $7.7 million in 2023, then increased by 5.42% to $8.2 million in 2024, then grew by 10.52% to $9.0 million in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Shares Outstanding (Diluted Average) are $9.0 million (Q4 2025), $9.0 million (Q3 2025), and $8.2 million (Q4 2024).